Stock Events

Stock Events

Adial Pharmaceuticals 

$1.79
44
+$0.08+4.68% Tuesday 20:00

Statistics

Day High
1.85
Day Low
1.7
52W High
30.25
52W Low
1.54
Volume
97,934
Avg. Volume
82,995
Mkt Cap
42.94M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-3.5
-2.39
-1.29
-0.18
Expected EPS
-2.25
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-26.39MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADIL. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes plc focuses on central nervous system (CNS) diseases, including addiction, which competes with Adial's focus on addiction treatments.
Indivior Pharmaceuticals
INDV
Mkt Cap3.67B
Indivior PLC offers products for the treatment of opioid dependence, directly competing with Adial's addiction treatment portfolio.
Opko Health
OPK
Mkt Cap1.04B
OPKO Health, Inc. has a diverse portfolio, including pharmaceuticals for addiction, making it a competitor in the addiction treatment market.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
ACADIA Pharmaceuticals Inc. focuses on CNS disorders, a market that overlaps with Adial's addiction and alcohol use disorder treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, potentially competing in the broader pharmaceutical market.
Jazz Pharmaceuticals
JAZZ
Mkt Cap8.35B
Jazz Pharmaceuticals plc has a portfolio that includes CNS treatments, competing in the same therapeutic area as Adial.
Supernus Pharmaceuticals
SUPN
Mkt Cap3.12B
Supernus Pharmaceuticals, Inc. focuses on developing and commercializing products for the treatment of CNS diseases, overlapping with Adial's market.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries Limited operates in generic and specialty medicines, including CNS and addiction treatments, making it a broad competitor.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals Incorporated is involved in creating transformative medicines for people with serious diseases, potentially competing in innovation and market share.

About

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Show more...
CEO
Mr. Cary John Claiborne MBA
Employees
5
Country
US
ISIN
US00688A3041

Listings

XNAS
US
ADIL
BOATS
BOATS
ADIL.BOATS

0 Comments

Share your thoughts

FAQ

What is Adial Pharmaceuticals stock price today?▼
The current price of ADIL is $1.79 USD — it has increased by +4.68% in the past 24 hours. Watch Adial Pharmaceuticals stock price performance more closely on the chart.
What is Adial Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Adial Pharmaceuticals stocks are traded under the ticker ADIL.
Is Adial Pharmaceuticals stock price growing?▼
ADIL stock has risen by +3.47% compared to the previous week, the month change is a -29.25% fall, over the last year Adial Pharmaceuticals has showed a -89.09% decrease.
What is Adial Pharmaceuticals market cap?▼
Today Adial Pharmaceuticals has the market capitalization of 42.94M
When is the next Adial Pharmaceuticals earnings date?▼
Adial Pharmaceuticals is going to release the next earnings report on May 20, 2026.
What were Adial Pharmaceuticals earnings last quarter?▼
ADIL earnings for the last quarter are -1.81 USD per share, whereas the estimation was -2.13 USD resulting in a +15.02% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adial Pharmaceuticals revenue for the last year?▼
Adial Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Adial Pharmaceuticals net income for the last year?▼
ADIL net income for the last year is -26.39M USD.
How many employees does Adial Pharmaceuticals have?▼
As of April 01, 2026, the company has 5 employees.
In which sector is Adial Pharmaceuticals located?▼
Adial Pharmaceuticals operates in the Health Care sector.
When did Adial Pharmaceuticals complete a stock split?▼
The last stock split for Adial Pharmaceuticals was on February 06, 2026 with a ratio of 1:25.
Where is Adial Pharmaceuticals headquartered?▼
Adial Pharmaceuticals is headquartered in Glen Allen, US.